Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 12 EBITDA Margin % is -12.10% as of Dec. 2024. GuruFocus rates XPAR:MLBON with a GF Score™ of 12/100 and a GF Value™ of €8.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Bonyf NV ranks worse than 69.24% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bonyf NV's EBITDA for the
six
months ended in Dec. 2024 was €-0.03 Mil. Bonyf NV's Revenue for the
six
months ended in Dec. 2024 was €0.28 Mil. Therefore, Bonyf NV's EBITDA margin for the quarter that ended in Dec. 2024 was -12.10%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bonyf NV EBITDA Margin % Related Terms
Bonyf NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bonyf NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV EBITDA Margin % Chart
Bonyf NV Annual Data
Trend
Dec19
Dec20
Dec22
Dec23
Dec24
EBITDA Margin %
8.38
0.17
-96.39
-12.94
-12.10
Bonyf NV Semi-Annual Data
Dec19
Dec20
Dec22
Dec23
Dec24
EBITDA Margin %
8.38
0.17
-96.39
-12.94
-12.10
XPAR:MLBON vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bonyf NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonyf NV EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonyf NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bonyf NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV (XPAR:MLBON) has a EBITDA Margin % of -12.10% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bonyf NV and its competitors. According to the industry distribution chart, Bonyf NV ranks #565 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 69.2%.
Is Bonyf NV's EBITDA Margin % too high?
Bonyf NV's current EBITDA Margin % is -12.10%. Based on the distribution chart, Bonyf NV ranks #565 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bonyf NV has a GF Score™ of 12/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #565 out of 816 companies for EBITDA Margin %. This places Bonyf NV in the lower half of its industry. The industry median EBITDA Margin % is 7.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bonyf NV and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current EBITDA Margin % is -12.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.61, compared to a current price of €2.48 — trading 71.2% below its estimated fair value. The current EBITDA Margin % is -12.10%. Bonyf NV's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current EBITDA Margin % is -12.10% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 71.2% below its estimated GF Value™ of €8.61.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
EBITDA Margin %: -12.10%
GF Value™: €8.61 vs. price of €2.48 (71.2% below fair value)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
12GF Score
Get the complete analysis for XPAR:MLBON
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
